메뉴 건너뛰기




Volumn 54, Issue 12, 2011, Pages 2978-2986

Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: A multicentre, randomised, placebo-controlled study

Author keywords

Angiotensin receptor blocker; Diabetic nephropathy; Macroproteinuria; Type 2 diabetes

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INSULIN; OLMESARTAN; ORAL ANTIDIABETIC AGENT; PLACEBO; POTASSIUM SPARING DIURETIC AGENT;

EID: 82455162519     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-011-2325-z     Document Type: Article
Times cited : (202)

References (29)
  • 1
    • 70449633330 scopus 로고    scopus 로고
    • Ministry of Health, Labor and Welfare Accessedon24April2009
    • Ministry of Health, Labor and Welfare (2009) National Health and Nutrition Survey in 2007. www.mhlw.go.jp/houdou/2008/12/h1225-5.html. Accessed on 24 April 2009
    • (2009) National Health and Nutrition Survey in 2007
  • 2
    • 0034534774 scopus 로고    scopus 로고
    • Fibrinogen, other cardiovascular risk factors and diabetes mellitus in Hong Kong: A community with high prevalence of Type 2 diabetes mellitus and impaired glucose tolerance
    • DOI 10.1046/j.1464-5491.2000.00384.x
    • TH Lam LJ Liu ED Janus KSL Lam AJ Hedley 2000 Fibrinogen, other cardiovascular risk factors and diabetes mellitus in Hong Kong Chinese: a community with high prevalence of type 2 diabetes mellitus and impaired glucose tolerance Diabetic Med 17 798 806 11131105 10.1046/j.1464-5491.2000.00384.x 1:STN:280:DC%2BD3M7jslanug%3D%3D (Pubitemid 32000979)
    • (2000) Diabetic Medicine , vol.17 , Issue.11 , pp. 798-806
    • Lam, T.H.1    Liu, L.J.2    Janus, E.D.3    Lam, K.S.L.4    Hedley, A.J.5
  • 3
    • 0035856920 scopus 로고    scopus 로고
    • Global and societal implications of the diabetes epidemic
    • DOI 10.1038/414782a
    • P Zimmet KG Alberti J Shaw 2001 Global and societal implications of the diabetes epidemic Nature 414 6865 782 787 11742409 10.1038/414782a 1:CAS:528:DC%2BD38Xhtlymtg%3D%3D (Pubitemid 34000780)
    • (2001) Nature , vol.414 , Issue.6865 , pp. 782-787
    • Zimmet, P.1    Alberti, K.G.M.M.2    Shaw, J.3
  • 4
    • 82455200902 scopus 로고    scopus 로고
    • Excerpts from the United States Renal Data System 2008 Annual Data Report: International comparison
    • United States Renal Data System
    • United States Renal Data System (2009) Excerpts from the United States Renal Data System 2008 Annual Data Report: International comparison. Am J Kidney Dis 53(Suppl 1):S297-S308
    • (2009) Am J Kidney Dis , vol.53 , Issue.SUPPL 1
  • 5
    • 84855294188 scopus 로고    scopus 로고
    • Japanese Society of Dialysis Therapy: An overview of regular dialysis treatment in Japan as of Dec 31, 2007 Accessed24April2009
    • Japanese Society of Dialysis Therapy: An overview of regular dialysis treatment in Japan as of Dec 31, 2007. http://docs.jsdt.or.jp/overview/. Accessed 24 April 2009
  • 7
    • 47649091344 scopus 로고    scopus 로고
    • Microvascular disease: What does the UKPDS tell us about diabetic nephropathy?
    • DOI 10.1111/j.1464-5491.2008.02496.x
    • R Bilous 2008 Microvascular disease: what does the UKPDS tell us about diabetic nephropathy? Diabet Med 25 Suppl 2 25 29 18717975 10.1111/j.1464-5491. 2008.02496.x (Pubitemid 352020092)
    • (2008) Diabetic Medicine , vol.25 , Issue.SUPPL. 2 , pp. 25-29
    • Bilous, R.1
  • 8
    • 0033852481 scopus 로고    scopus 로고
    • Preserving renal function in adults with hypertension and diabetes: A consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group
    • 10977801 10.1053/ajkd.2000.16225 1:STN:280:DC%2BD3cvjsFSqsw%3D%3D
    • GL Bakris M Williams L Dworkin, et al. 2000 Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group Am J Kidney Dis 36 646 661 10977801 10.1053/ajkd.2000.16225 1:STN:280: DC%2BD3cvjsFSqsw%3D%3D
    • (2000) Am J Kidney Dis , vol.36 , pp. 646-661
    • Bakris, G.L.1    Williams, M.2    Dworkin, L.3
  • 9
    • 0035922441 scopus 로고    scopus 로고
    • Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
    • 11565518 10.1056/NEJMoa011161 1:CAS:528:DC%2BD3MXntlelsLk%3D
    • BM Brenner ME Cooper D de Zeeuw, et al. 2001 Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 861 869 11565518 10.1056/NEJMoa011161 1:CAS:528: DC%2BD3MXntlelsLk%3D
    • (2001) N Engl J Med , vol.345 , pp. 861-869
    • Brenner, B.M.1    Cooper, M.E.2    De Zeeuw, D.3
  • 10
    • 0035922447 scopus 로고    scopus 로고
    • Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
    • 11565517 10.1056/NEJMoa011303 1:CAS:528:DC%2BD3MXntlelsLg%3D
    • EJ Lewis LG Hunsicker WR Clarke, et al. 2001 Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 345 851 860 11565517 10.1056/NEJMoa011303 1:CAS:528:DC%2BD3MXntlelsLg%3D
    • (2001) N Engl J Med , vol.345 , pp. 851-860
    • Lewis, E.J.1    Hunsicker, L.G.2    Clarke, W.R.3
  • 12
    • 33749356700 scopus 로고    scopus 로고
    • Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: A subanalysis of Japanese patients from the RENAAL study
    • DOI 10.1007/s10157-006-0427-6
    • K Kurokawa JC Chan ME Cooper WF Keane S Shahinfar Z Zhang 2006 Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL Study Clin Exp Nephrol 10 193 200 17009077 10.1007/s10157-006-0427-6 1:CAS:528: DC%2BD28XhtFOrsbfK (Pubitemid 44496891)
    • (2006) Clinical and Experimental Nephrology , vol.10 , Issue.3 , pp. 193-200
    • Kurokawa, K.1    Chan, J.C.N.2    Cooper, M.E.3    Keane, W.F.4    Shahinfar, S.5    Zhang, Z.6
  • 13
    • 33646919559 scopus 로고    scopus 로고
    • Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine
    • DOI 10.1136/bmj.38803.528113.55
    • SE McDowell JJ Coleman RE Ferner 2006 Systemic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine BMJ 332 1177 1181 16679330 10.1136/bmj.38803.528113.55 1:CAS:528:DC%2BD28XmtFamt7Y%3D (Pubitemid 44365446)
    • (2006) British Medical Journal , vol.332 , Issue.7551 , pp. 1177-1180
    • McDowell, S.E.1    Coleman, J.J.2    Ferner, R.E.3
  • 14
    • 49149087718 scopus 로고    scopus 로고
    • Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET Study): A multicentre, randomised, double-blind, controlled trial
    • 18707986 10.1016/S0140-6736(08)61236-2 1:CAS:528:DC%2BD1cXpvFKgsLs%3D
    • JF Mann RE Schmieder M McQueen, et al. 2008 Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET Study): a multicentre, randomised, double-blind, controlled trial Lancet 372 547 553 18707986 10.1016/S0140-6736(08)61236-2 1:CAS:528:DC%2BD1cXpvFKgsLs%3D
    • (2008) Lancet , vol.372 , pp. 547-553
    • Mann, J.F.1    Schmieder, R.E.2    McQueen, M.3
  • 15
    • 77953395873 scopus 로고    scopus 로고
    • CONSORT 2010 statement: Updated guidelines for reporting parallel group randomized trials
    • the CONSORT Group
    • KF Schwaltz DG Altman D Moher the CONSORT Group 2010 CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials Ann Intern Med 152 726 732
    • (2010) Ann Intern Med , vol.152 , pp. 726-732
    • Schwaltz, K.F.1    Altman, D.G.2    Moher, D.3
  • 16
    • 33750209033 scopus 로고    scopus 로고
    • Olmesartan Reducing Incidence of Endstage Renal Disease in Diabetic Nephropathy trial (ORIENT): Rationale and study design
    • E Imai S Ito M Haneda JC Chan H Makino 2006 Olmesartan Reducing Incidence of Endstage Renal Disease in Diabetic Nephropathy Trial (ORIENT): rationale and study design Hypertens Res 29 703 709 17249526 10.1291/hypres.29.703 1:CAS:528:DC%2BD28XhtlartrfK (Pubitemid 44605369)
    • (2006) Hypertension Research , vol.29 , Issue.9 , pp. 703-709
    • Imai, E.1    Ito, S.2    Haneda, M.3    Chan, J.C.N.4    Makino, H.5
  • 17
    • 0030818790 scopus 로고    scopus 로고
    • Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: A meta-analysis of randomized trials
    • I Giatras J Lau AS Levey 1997 Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group Ann Intern Med 127 337 345 9273824 1:CAS:528:DyaK2sXmt1Wksb4%3D (Pubitemid 27362741)
    • (1997) Annals of Internal Medicine , vol.127 , Issue.5 , pp. 337-345
    • Giatras, I.1    Lau, J.2    Levey, A.S.3
  • 18
    • 0000336139 scopus 로고
    • Regression models and life-tables
    • DR Cox 1972 Regression models and life-tables J R Stat Soc [B] 34 187 220
    • (1972) J R Stat Soc [B] , vol.34 , pp. 187-220
    • Cox, D.R.1
  • 19
    • 33845382806 scopus 로고
    • Nonparametric estimation from incomplete observations
    • 10.2307/2281868
    • EL Kaplan P Meier 1958 Nonparametric estimation from incomplete observations J Am Stat Assoc 53 457 481 10.2307/2281868
    • (1958) J Am Stat Assoc , vol.53 , pp. 457-481
    • Kaplan, E.L.1    Meier, P.2
  • 20
    • 0034585310 scopus 로고    scopus 로고
    • The losartan renal protection study-rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the AngiotensinII Antagonist Losartan)
    • 11967819 10.3317/jraas.2000.062 1:CAS:528:DC%2BD3MXhsFGktb0%3D
    • BM Brenner ME Cooper D de Zeeuw, et al. 2000 The losartan renal protection study-rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the AngiotensinII Antagonist Losartan) J Renin Angiotensin Aldosterone Syst 1 328 335 11967819 10.3317/jraas.2000.062 1:CAS:528:DC%2BD3MXhsFGktb0%3D
    • (2000) J Renin Angiotensin Aldosterone Syst , vol.1 , pp. 328-335
    • Brenner, B.M.1    Cooper, M.E.2    De Zeeuw, D.3
  • 21
    • 34249899918 scopus 로고    scopus 로고
    • Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes
    • DOI 10.2337/dc06-1998
    • H Makino M Haneda T Babazono, et al. 2007 Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes Diabetes Care 30 1577 1578 17389334 10.2337/dc06-1998 1:CAS:528: DC%2BD2sXntlWkt7g%3D (Pubitemid 46871174)
    • (2007) Diabetes Care , vol.30 , Issue.6 , pp. 1577-1578
    • Makino, H.1    Haneda, M.2    Babazono, T.3    Moriya, T.4    Ito, S.5    Iwamoto, Y.6    Kawamori, R.7    Takeuchi, M.8    Katayama, S.9
  • 22
    • 34249905442 scopus 로고    scopus 로고
    • Reduction of microalbuminuria in patients with type 2 diabetes. The Shiga Microalbuminuria Reduction Trial (SMART)
    • DOI 10.2337/dc06-2493
    • T Uzu M Sawaguchi H Maegawa A Kashiwagi 2007 Reduction of microalbuminuria in patients with type 2 diabetes: the Shiga Microalbuminuria Reduction Trial (SMART) Diabetes Care 30 1581 1583 17363751 10.2337/dc06-2493 (Pubitemid 46871176)
    • (2007) Diabetes Care , vol.30 , Issue.6 , pp. 1581-1583
    • Kashiwagi, A.1
  • 23
    • 0037031270 scopus 로고    scopus 로고
    • Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressure-independent effect
    • DOI 10.1161/01.CIR.0000024416.33113.0A
    • G Viberti NM Wheeldon 2002 Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect Circulation 106 672 678 12163426 10.1161/01.CIR.0000024416.33113.0A 1:CAS:528:DC%2BD38XmvFSmsL8%3D (Pubitemid 34851925)
    • (2002) Circulation , vol.106 , Issue.6 , pp. 672-678
    • Viberti, G.1    Wheeldon, N.M.2
  • 24
    • 0034627208 scopus 로고    scopus 로고
    • Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The Candesartan and Lisinopril Microalbuminuria (CALM) Study
    • 11110735 10.1136/bmj.321.7274.1440 1:CAS:528:DC%2BD3MXjsFCkuw%3D%3D
    • CE Mogensen S Neldam I Tikkanen, et al. 2000 Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the Candesartan and Lisinopril Microalbuminuria (CALM) Study BMJ 321 7274 1440 1444 11110735 10.1136/bmj.321.7274.1440 1:CAS:528:DC%2BD3MXjsFCkuw%3D%3D
    • (2000) BMJ , vol.321 , Issue.7274 , pp. 1440-1444
    • Mogensen, C.E.1    Neldam, S.2    Tikkanen, I.3
  • 25
    • 0035922444 scopus 로고    scopus 로고
    • The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
    • 11565519 10.1056/NEJMoa011489 1:CAS:528:DC%2BD3MXntlelsLY%3D
    • H-H Parving H Lehnert J Brochner-Mortensen R Gomis S Andersen P Arner 2001 The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes N Engl J Med 345 870 878 11565519 10.1056/NEJMoa011489 1:CAS:528:DC%2BD3MXntlelsLY%3D
    • (2001) N Engl J Med , vol.345 , pp. 870-878
    • Parving, H.-H.1    Lehnert, H.2    Brochner-Mortensen, J.3    Gomis, R.4    Andersen, S.5    Arner, P.6
  • 28
    • 0035818884 scopus 로고    scopus 로고
    • A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure
    • DOI 10.1056/NEJMoa010713
    • JN Cohn G Tognoni 2001 A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure N Engl J Med 6 345 1667 1675 10.1056/NEJMoa010713 (Pubitemid 33126822)
    • (2001) New England Journal of Medicine , vol.345 , Issue.23 , pp. 1667-1675
    • Cohn, J.N.1    Tognoni, G.2
  • 29
    • 0041408235 scopus 로고    scopus 로고
    • Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-added trial
    • DOI 10.1016/S0140-6736(03)14283-3
    • JJ McMurray J Ostergren K Swedberg, et al. 2003 Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial Lancet 362 767 771 13678869 10.1016/S0140-6736(03)14283-3 1:CAS:528: DC%2BD3sXntVGktLo%3D (Pubitemid 37093916)
    • (2003) Lancet , vol.362 , Issue.9386 , pp. 767-771
    • McMurray, J.J.V.1    Ostergren, J.2    Swedberg, K.3    Granger, C.B.4    Held, P.5    Michelson, E.L.6    Olofsson, B.7    Yusuf, S.8    Pfeffer, M.A.9


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.